Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KMPH - Zevra Therapeutics Inc


Previous close
5.46
0   0%

Share volume: 0
Last Updated: Wed 01 Mar 2023 06:00:00 AM CET
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%

$5.46
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
38%
Profitability 45%
Dept financing 25%
Liquidity 8%
Performance 40%
Company vs Stock growth
vs
Performance
5 Days
4.36%
1 Month
4.36%
3 Months
20.59%
6 Months
-9.18%
1 Year
-2.05%
2 Year
-34.10%
Key data
Stock price
$5.46
P/E Ratio 
0.00
DAY RANGE
$5.46 - $5.98
EPS 
$0.00
52 WEEK RANGE
$4.00 - $6.92
52 WEEK CHANGE
-$0.02
MARKET CAP 
198.058 M
YIELD 
N/A
SHARES OUTSTANDING 
34.505 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.78
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$184,472
AVERAGE 30 VOLUME 
$137,517
Company detail
CEO: Travis Mickle
Region: US
Website: www.kempharm.com
Employees: 24
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

Recent news